Editorial

Pneumococcal vaccine

Vaccination against pneumococcal pneumonia has a long history. It began with a whole cell vaccine 70 years ago and developed through the discovery of pneumococcal typing and subdivision of the species by capsular antigens. This led to passive immunisation as a form of treatment and to the first type specific vaccines in the 1930s. After the serum and antibiotics there was less interest in serum treatment and vaccination. The death rate in the first five years of an attack of bacteraemic pneumonia was not decreased, however, and the case fatality rate from pneumococcal bacteraemia remained a substantial 20%. So research continued to make purified polysaccharide multiple type (polyvalent) vaccines and these proved to be successful in trials reported 10 years ago. Further developments increased the range of pneumococcal types covered by the vaccines—from six to 12, 14, 17, and now 23 types. These modern vaccines deserve more attention than they have received outside the United States.

Risks of pneumococcal infection

The incidence of pneumococcal pneumonia in Britain is about 1/1000 a year, to judge by the 1984–5 Nottingham study. In another study in the same city the mortality from community acquired pneumococcal pneumonia treated in hospital was 18%, a figure that echoes case fatality rates in New York 20 years earlier. The incidence is more than 10 times higher in the elderly and in patients with asplenia, Hodgkin's disease, myeloma, heart disease, chronic obstructive pulmonary disease, diabetes, cirrhosis, and renal failure (the evidence has been usefully summarised by Mufson). The infections are more severe and the mortality higher in these patients. Although it may be said that pneumonia is the old man's friend, even elderly patients may regard the friend's arrival as premature.

American policy

In the United States pneumococcal vaccination is recommended for adults with chronic cardiovascular or pulmonary disease, adults and children aged over 2 years with the conditions that carry an increased risk of pneumococcal disease (see above), and all healthy adults aged 65 or more. These recommendations are endorsed by the American College of Physicians and the American Academy of Pediatrics, and reinforced by federal funding for Medicare to pay for vaccination. Although these recommendations were based on few controlled trials, there is increasing evidence of the efficacy of the 14 polysaccharide vaccine (see below). But not all the earlier doubts can be dispelled, as shown by a recently reported controlled trial carried out by the American Veterans Administration. Moreover, many people entitled to vaccine have not received it: up to 1985 only 10-7% of adults over 65 years and 7-1% of people in high risk groups in the United States had been vaccinated. It is timely to consider how pneumococcal vaccine might best be used in other countries.

Modern vaccines

The present day pneumococcal vaccines are purified type specific polysaccharides, containing 50 μg of each type in the 12, 14, and 17 valent vaccines used before 1984, or 25 μg in the newer 23 valent vaccine. These amounts are contained in a volume of 0.5 ml for intramuscular injection. The component types in the vaccines cover 80–90% of the types causing serious infection. Minor reactions to vaccination are common: mild soreness and induration at the site of the injection in 27% of 5946 people vaccinated in a double blind controlled trial, with low grade fever in 7%. There were no serious reactions. Revaccination at intervals of less than five years may cause more severe reactions. There was a problem with a 14 valent vaccine producing ABO blood group antibodies, but this difficulty has been overcome with further purification in manufacture. In the United States more than 5 million doses have been given without more serious adverse reactions in people given only one dose.
Evidence of efficacy

The efficacy of pneumococcal vaccines has been assessed by measuring antibody titres after vaccination, by controlled clinical trials, and by surveillance of the incidence of disease in vaccinated people. A single dose of vaccine induces a good antibody response in normal healthy adults, 90% having a rise in antibody titres to all pneumococcal types. Not so satisfactory is the response in children less than 2 years old and patients with impairment of immunity due to lymphomas, renal failure or asplenism.\textsuperscript{18-21} In these people antigen types 6A, 14, 19F, and 23F are less likely to produce antibodies, and the mean post-vaccination antibody titres tend to be less than in healthy adults. For some time there was doubt about the relationship between antibody response and clinical efficacy, but the results of clinical trials suggest that antibody titres below 256 ng immunoglobulin nitrogen/ml indicate a lack of immunity. Serum antibody titres, however, are not the only determinant of clinical efficacy because other factors are needed to protect against infection with capsulated bacteria. Patients with chronic obstructive lung disease may produce antibodies but be unable to opsonise pneumococci as well as normal subjects.\textsuperscript{22,23}

The early controlled clinical trials of polyvalent polysaccharide vaccines in goldminers in South Africa\textsuperscript{2} and adults and children in Papua New Guinea\textsuperscript{24} produced very promising results. Both groups had a high incidence of pneumococcal pneumonia, which the vaccines reduced by 76–92%. A study in children with sickle cell disease and in children who had had splenectomy also pointed to the vaccine's efficacy,\textsuperscript{25} but a more formal randomised controlled trial in Jamaica, in children under 6 years old with sickle cell disease, found that vaccination was not protective (in contrast to penicillin prophylaxis).\textsuperscript{26} A trial by the American Veterans Administration in 2295 patients vaccinated according to the national recommendations found no significant reduction of pneumococcal respiratory infections.\textsuperscript{14} This trial has been criticised because its numbers, although substantial, may have been too small to test efficacy against bacteraemic disease, the key target for vaccination.\textsuperscript{27} Difficulties in achieving significant results and demonstrating protection have also been experienced in trials in elderly people.\textsuperscript{28}

Alternative methods of assessing clinical efficacy have been proposed.\textsuperscript{29} In a retrospective study at Yale–New Haven Hospital Shapiro and Clemens\textsuperscript{30} compared the vaccination histories of 90 patients with pneumococcal disease with those of patients matched for age and sex. They estimated that pneumococcal vaccine had an overall efficacy of 67%, or higher if the estimate was calculated for patients aged 55 years or more (70% efficacy) and for patients with "moderately increased risk" of pneumococcal infection (77% efficacy). They could not confirm protection in patients with the highest risk of infection (immunodeficiency), but they had few such patients in their study. The words "high risk" can confuse: high risk in the Veterans trial\textsuperscript{14} is similar to moderate risk in the Yale–New Haven study and is applied to patients with chronic pulmonary, cardiac, and renal diseases and alcoholism. By a clever use of the fact that specific types are either present or absent from the vaccine, Broome and her colleagues at the Centre for Disease Control, Atlanta, Georgia, devised a means of calculating vaccine protection from reports of pneumococcal bacteraemia and meningitis.\textsuperscript{31} From 187 episodes of bacteraemia in vaccinated people and 1447 episodes in unvaccinated patients vaccination was found to be 64% effective in preventing pneumococcal bacteraemia overall. It was much less effective in patients with Hodgkin's disease, multiple myeloma, and renal failure.\textsuperscript{32}

Duration of immunity

The duration of the raised antibody titres induced by the vaccine is still a matter of uncertainty. Children are normally exposed to most if not all of the common types of pneumococci, which cause otitis media in some, with a very small risk (in healthy children) of pneumonia and meningitis. The natural history of pneumococcal disease implies that immunity declines with age and chronic illness. Pneumococci remain a part of the normal flora of the respiratory tract, so a state of peaceful coexistence may be maintained so long as the host has a competent immune system (including a functioning spleen). Presumably there are times when this condition is not fulfilled and a breach in the defences occurs, so that disease results. Thus the role of pneumococcal vaccine is to enhance the immunological experience of childhood with reinforcing challenges of antigen. Hence the duration of immunity is hard to calculate, and must be found by measuring antibodies and observing the incidence of disease in those who have been vaccinated. Asplenic children and patients having haemodialysis have been found to have falling antibody titres within four years, and they continue to be at risk of pneumococcal bacteraemia despite vaccination. Repeated vaccination may be useful in these patients.\textsuperscript{33-35} As a general rule, revaccination is not recommended, because of the higher incidence of reactions.\textsuperscript{8}

Organisation of vaccination

Patients who have medical indications for pneumococcal vaccine are likely to be receiving con-
tinuous medical care for their chronic diseases. Vaccination should not therefore be difficult to arrange or unduly expensive by comparison with other drugs. It has been suggested that vaccine should be given when patients are in hospital.\textsuperscript{36,37} In the Oxford region 4.8\% of patients who had been in hospital for any reason were readmitted within five years with pneumonia,\textsuperscript{38} of whom 34\% might be expected to have pneumococcal pneumonia.\textsuperscript{39} Without evidence from a controlled clinical trial or retrospective evaluation, however, it is not clear whether immunisation of patients at high risk (by the different means of providing vaccine, with monitoring on the uptake of vaccine and the effect on hospital admissions and deaths from pneumococcal pneumonia.

It has been estimated that for every $6000 (1983 prices) spent on vaccinating 65 year old Americans, one extra year of healthy life is gained.\textsuperscript{40} If protection lasted for eight years and if administrative arrangements were improved, vaccination could have financial as well as humanitarian value. This suggests that other countries should examine the cost-effectiveness of pneumococcal vaccination and compare it with their other public health activities. Modern vaccines require heavy investment in development and manufacture. If little vaccine is used, because of a very selective policy or because physicians show little interest in this form of prevention, there may be no advantage to a pharmaceutical firm in licensing and distributing the vaccine. A substantial investment is required to run good vaccination programmes, not least to win public interest.

Conclusions

We are near the limits of what can be gained by theoretical arguments without practical experiments in public programmes of pneumococcal vaccination. Given current knowledge, a ready supply of vaccine, and some arbitrary age limits, my policy would be to offer a single dose of 23 valent vaccine to:

1. Patients aged 55–70 with chronic diseases of the heart, lungs, or liver or with diabetes, provided that they were not expected to die from their underlying condition within the next year. The vaccine should be given when the patient is not acutely ill.
2. Patients aged 2–70 with chronic renal disease, sickle cell disease, or asplenism, again at a time when they are not acutely ill. The vaccine should preferably be given before splenectomy (if applicable) and certainly not during periods of intense immunosuppression. Because vaccination is not reliable in these conditions, the patients should be advised to seek medical advice at the first symptoms of infection. Children with sickle cell disease or other forms of asplenism should in addition have penicillin prophylaxis.

The vaccination should be clearly recorded in the hospital and general practice notes. The usage of vaccine should be monitored nationally, and its efficacy should be assessed periodically by retrospective studies. These require accurate diagnosis of pneumonia, with pneumococcal typing of all relevant isolates.

As the vaccines have not proved effective in reducing pneumococcal bacteraemia in patients with multiple myeloma or Hodgkin’s disease, these conditions are not included in my list of indications. Vaccination in pregnancy is not recommended. At present, revaccination is not indicated, even for those who were given 14 valent vaccine several years ago.

When we have vaccinated most if not all patients in the higher risk groups, we should consider whether the benefits (if such they are) can be shared more widely. I look forward to the time when pneumococcal vaccination is part of everyone’s preretirement course.

RT Mayon White
District Department of Community Medicine
Oxford

References

7 Mufson MA. Pneumococcal Infections \textit{JAMA} 1981;


29 Clemens JD, Shapiro ED. Resolving the pneumococcal vaccine controversy: are there alternatives to randomised clinical trials? Rev Infect Dis 1984;6:589–600.


Pneumococcal vaccine.

R T White

*Thorax* 1988 43: 345-348
doi: 10.1136/thx.43.5.345

Updated information and services can be found at:
http://thorax.bmj.com/content/43/5/345.citation

**Email alerting service**

*These include:*

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/